Safety Study of Polylactide-Caprolactone-Trimethylenecarbonate Copolymer for Post-Operative Adhesion Prophylaxis

NCT ID: NCT00597662

Last Updated: 2008-06-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare adhesion prophylaxis with polylactide-caprolactone-trimethylenecarbonate copolymer to icodextrin 4% in terms of safety, side effects and usability in addition to gaining early evidence of the effectiveness of polylactide-caprolactone-trimethylenecarbonate copolymer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adhesions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

polylactide-caprolactone-trimethylenecarbonate copolymer

Intervention Type DEVICE

Polylactide-caprolactone-trimethylenecarbonate copolymer membrane is applied directly over the surgical scar on the visceral peritoneum

2

Group Type ACTIVE_COMPARATOR

Icodextrin 4%

Intervention Type DEVICE

1 liter icodextrin 4% is instilled into the peritoneal cavity at the end of the operation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

polylactide-caprolactone-trimethylenecarbonate copolymer

Polylactide-caprolactone-trimethylenecarbonate copolymer membrane is applied directly over the surgical scar on the visceral peritoneum

Intervention Type DEVICE

Icodextrin 4%

1 liter icodextrin 4% is instilled into the peritoneal cavity at the end of the operation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 18-60 years
* sex female
* laparoscopic myomectomy indicated
* ability and intention to conform to the study protocol
* written informed consent

Exclusion Criteria

* pregnancy
* indication for laparotomy
* inflammatory bowel disease
* additional surgical interventions
* known or suspected intollerance or hypersensibility to the interventions
* chronic pain
* systemic corticoids or irradiation
* alcohol abuse or other substance abuse
* clinical signs of malignancy
* psychiatric or neurological disease
* participation in another clinical trial within 30 days
* inability to understand the purpose of the trial or to conform to the study protocol
* absence of written informed consent
* inflammation of pelvic organs
* presence of adhesions which lead to a conversion from laparoscopy to laparotomy
* concurrent therapy with corticoids, anti-neoplastic agents or irradiation
* maintenance therapy with non-steroidal anti-inflammatory drugs or analgesics
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Tuebingen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Universitäts-Frauenklinik Tübingen

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Diethelm Wallwiener, Prof. Dr.

Role: STUDY_CHAIR

Universitäts-Frauenklinik Tübingen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universitäts-Frauenklinik Tübingen

Tübingen, Baden-Wurttemberg, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SUP-002

Identifier Type: -

Identifier Source: org_study_id